info@seagull-health.com
SeagullHealth
search
Faricimab-svoa(Vabysmo)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Vabysmo(Faricimab-svoa) Instructions:Uses,Dosage, Side Effects
VABYSMO (faricimab-svoa) is a humanized bispecific immunoglobulin G1 antibody that inhibits both vascular endothelial growth factor A and angiopoietin-2. It is supplied as a sterile solution in single-dose prefilled syringes or vials for intravitreal use. The medication reduces endothelial cell proliferation and vascular permeability while promoting vascular stability, aiding in the management of retinal conditions. It is produced using recombinant DNA technology in mammalian cell culture.
Neovascular (Wet) Age-Related Macular Degeneration (nAMD).
Diabetic Macular Edema (DME).
Macular Edema Following Retinal Vein Occlusion (RVO).
nAMD: 6 mg via intravitreal injection every 4 weeks for the first 4 doses, followed by individualized dosing intervals (e.g., every 8–16 weeks) based on optical coherence tomography and visual acuity assessments.
DME: Two regimens are recommended:
6 mg every 4 weeks for at least 4 doses, with subsequent interval adjustments (extended up to 4 weeks or reduced up to 8 weeks) based on central subfield thickness and visual acuity.
6 mg every 4 weeks for the first 6 doses, then every 8 weeks.
RVO: 6 mg administered every 4 weeks for 6 months.
All injections must be performed using aseptic technique.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
